• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CLDI alert in real time by email
    SC 13G 1 cldi.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

    Calidi Biotherapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

     

    (Title of Class of Securities)

     

    320703309

    (CUSIP Number)

     

    September 4, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 320703309   13G   Page 2 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Funicular Funds, LP

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1)

    The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2) The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

     

     

    CUSIP No. 320703309   13G   Page 3 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Cable Car Capital LLC (3)

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    California

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     
    ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, PN

     

    (1) The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2)The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    (3)

    Cable Car Capital LLC, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital LLC, may each be deemed the beneficial owner of the shares held by Funicular Funds, LP.

     

     

     

    CUSIP No. 320703309   13G   Page 4 of 8 Pages

     

    1.

    NAMES OF REPORTING PERSONS

     

    Jacob Ma-Weaver (3)

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)  ☐

    (b)  ☐

    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

    5.

    SOLE VOTING POWER

     

    897,241 (1)(2)
    6.

    SHARED VOTING POWER

     

     -0-
    7.

    SOLE DISPOSITIVE POWER

     

    897,241 (1)(2)
    8.

    SHARED DISPOSITIVE POWER

     

     -0-
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    897,241 (1)(2)
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)     ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99% (1)(2)

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

    (1) The reporting person’s beneficial ownership consists of (a) one share of common stock and (b) a convertible promissory note that became convertible at the option of the holder on September 4, 2024 (the “Note”).

     

    (2)The Note includes a provision limiting the holder’s ability to convert the Note if such conversion would cause the holder to beneficially own greater than 9.99% of the issuer. The foregoing calculation is based upon 8,084,153 shares of common stock outstanding as reported by the issuer on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024.

     

    (3)Cable Car Capital LLC, as the General Partner of Funicular Funds, LP, and Jacob Ma-Weaver, as the Managing Member of Cable Car Capital LLC, may each be deemed the beneficial owner of the shares held by Funicular Funds, LP.

     

     

     

    CUSIP No. 320703309   13G   Page 5 of 8 Pages

     

    Item 1.

     

    a.Name of Issuer

     

    Calidi Biotherapeutics, Inc.

     

    b.Address of Issuer’s Principal Executive Offices

     

    4475 Executive Drive, Suite 200, San Diego, CA 92121

     

    Item 2.

     

    (a)Name of Persons Filing

     

    Funicular Funds, LP

    Cable Car Capital LLC

    Jacob Ma-Weaver

     

    (b)Address of the Principal Office or, if none, residence

     

    601 California Street, #1151, San Francisco, CA 94108

     

    (c)Citizenship

     

    Funicular Funds, LP – Delaware

    Cable Car Capital LLC – California

    Jacob Ma-Weaver – United States

     

    (d)Title of Class of Securities

     

    Common Stock, $0.0001 par value

     

    (e)CUSIP Number

     

    320703309

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    CUSIP No. 320703309   13G   Page 6 of 8 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    (b)Percent of class:

     

    Funicular Funds, LP – 9.99%

     

    Cable Car Capital LLC – 9.99%

     

    Jacob Ma-Weaver – 9.99%

     

    (c)Number of shares as to which the person has:

     

    i.Sole power to vote or to direct the vote

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    ii.Shared power to vote or to direct the vote

     

    Funicular Funds, LP – 0

     

    Cable Car Capital LLC – 0

     

    Jacob Ma-Weaver – 0

     

    iii.Sole power to dispose or to direct the disposition of

     

    Funicular Funds, LP – 897,241

     

    Cable Car Capital LLC – 897,241

     

    Jacob Ma-Weaver – 897,241

     

    iv.Shared power to dispose or to direct the disposition of

     

    Funicular Funds, LP – 0

     

    Cable Car Capital LLC – 0

     

    Jacob Ma-Weaver – 0

     

    **See footnotes on cover pages which are incorporated by reference herein.

     

     

     

     

    CUSIP No. 320703309   13G   Page 7 of 8 Pages

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct.

     

    Dated: September 11, 2024    
         
      FUNICULAR FUNDS, LP
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member of the General Partner
         
      CABLE CAR CAPITAL LLC
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member
       
      JACOB MA-WEAVER
       
      By: /s/ Jacob Ma-Weaver
        Jacob Ma-Weaver

     

     

     

     

    CUSIP No. 320703309   13G   Page 8 of 8 Pages

     

    Exhibit A

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: September 11, 2024    
         
      FUNICULAR FUNDS, LP
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member of the General Partner
         
      CABLE CAR CAPITAL LLC
       
      By: /s/ Jacob Ma-Weaver
        Name: Jacob Ma-Weaver
        Title: Managing Member
       
      JACOB MA-WEAVER
       
      By: /s/ Jacob Ma-Weaver
        Jacob Ma-Weaver

     

     

     

     

     

    Get the next $CLDI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDI

    DatePrice TargetRatingAnalyst
    11/22/2023$11.00Buy
    H.C. Wainwright
    10/9/2023$9.00Outperform
    Robert W. Baird
    More analyst ratings

    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

    Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

    10/9/23 7:23:07 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma

    SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company's allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma. Fast Track designation is granted to products that are developed to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. This

    7/29/25 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

    SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ("Calidi" or the "Company") (NYSE:CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the "Reverse Stock Split"). The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of "CLDI." The new CUSIP number for the Company's common stock following the Reverse Stock Split will

    7/25/25 4:45:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Leftwich Scott

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:54 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Peoples George

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:56 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Schoeneck James A

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:59 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    SEC Filings

    View All

    SEC Form S-1 filed by Calidi Biotherapeutics Inc.

    S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    8/15/25 5:21:26 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Calidi Biotherapeutics Inc.

    SCHEDULE 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    8/14/25 9:05:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    8/14/25 5:18:36 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    Financials

    Live finance-specific insights

    View All

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

    Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

    3/31/25 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate

    10/25/24 9:00:00 AM ET
    $CLDI
    $NXL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

    4/25/25 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

    SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

    4/23/25 8:00:00 AM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care